Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Conditions: Gastric Cancer; Gastroesophageal-junction Cancer; Advanced Cancer Interventions: Drug: TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU); Drug: Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU) Sponsors: Suzhou Transcenta Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2023 Category: Research Source Type: clinical trials
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
Conditions: Diffuse Large B-cell Lymphoma Recurrent; Diffuse Large B Cell Lymphoma Refractory Interventions: Drug: Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin Sponsors: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2023 Category: Research Source Type: clinical trials
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma
Conditions: Clinical Stage I Esophageal Adenocarcinoma AJCC v8; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Endoscopic Ultrasound; Procedure: Esophagogastroduodenoscopy; Drug: Fluorouracil; Radiation: Hypofractionated Radiation Therapy; Drug: Leucovorin Calcium; Drug: Ox...
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma
Conditions: Gastrointestinal Neuroendocrine Carcinoma Interventions: Drug: Durvalumab and Chemotherapy(oxaliplatin and capecitabine) Sponsors: Peking Union Medical College Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Rectal Cancer
Conditions: Lymph Node Metastasis; Cancer of Rectum and Anus; Oxaliplatin; Intestinal Neoplasms; Gastrointestinal Neoplasms; Rectal Diseases; Rectal Neoplasms Interventions: Drug: Experimental: FOLFOXIRI and Lateral lymph node dissection; Drug: Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
Conditions: Gastric Cancer; Peritoneal Metastases; Ascites, Malignant Interventions: Drug: Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion; Other: Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected Sponsor: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Rectal Cancer
Conditions: Lymph Node Metastasis; Cancer of Rectum and Anus; Oxaliplatin; Intestinal Neoplasms; Gastrointestinal Neoplasms; Rectal Diseases; Rectal Neoplasms Interventions: Drug: Experimental: FOLFOXIRI and Lateral lymph node dissection; Drug: Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
Conditions: Gastric Cancer; Peritoneal Metastases; Ascites, Malignant Interventions: Drug: Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion; Other: Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected Sponsor: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Rectal Cancer
Conditions: Lymph Node Metastasis; Cancer of Rectum and Anus; Oxaliplatin; Intestinal Neoplasms; Gastrointestinal Neoplasms; Rectal Diseases; Rectal Neoplasms Interventions: Drug: Experimental: FOLFOXIRI and Lateral lymph node dissection; Drug: Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
Conditions: Gastric Cancer; Peritoneal Metastases; Ascites, Malignant Interventions: Drug: Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion; Other: Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected Sponsor: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Rectal Cancer
Conditions: Lymph Node Metastasis; Cancer of Rectum and Anus; Oxaliplatin; Intestinal Neoplasms; Gastrointestinal Neoplasms; Rectal Diseases; Rectal Neoplasms Interventions: Drug: Experimental: FOLFOXIRI and Lateral lymph node dissection; Drug: Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
Conditions: Gastric Cancer; Peritoneal Metastases; Ascites, Malignant Interventions: Drug: Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion; Other: Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected Sponsor: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Rectal Cancer
Conditions: Lymph Node Metastasis; Cancer of Rectum and Anus; Oxaliplatin; Intestinal Neoplasms; Gastrointestinal Neoplasms; Rectal Diseases; Rectal Neoplasms Interventions: Drug: Experimental: FOLFOXIRI and Lateral lymph node dissection; Drug: Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
Conditions: Gastric Cancer; Peritoneal Metastases; Ascites, Malignant Interventions: Drug: Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion; Other: Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected Sponsor: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Rectal Cancer
Conditions: Lymph Node Metastasis; Cancer of Rectum and Anus; Oxaliplatin; Intestinal Neoplasms; Gastrointestinal Neoplasms; Rectal Diseases; Rectal Neoplasms Interventions: Drug: Experimental: FOLFOXIRI and Lateral lymph node dissection; Drug: Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
